Public
1
Merck
Ethical Operating Standards
Handbook
Business Practices for U.S. Commercial
Related Activities
Public
Merck Ethical Operating Standards Handbook
1
Public
Table of Contents
Purpose........................................................................................................................................... 2
U.S. Laws and Regulations........................................................................................................... 2
Food and Drug Administration (FDA) Requirements ................................................................ 2
Government Pricing Requirements............................................................................................. 2
Medicaid Drug Rebate Statute and Medicare Laws ................................................................... 3
Federal and State Anti-Kickback Laws....................................................................................... 4
Federal and State False Claims Acts........................................................................................... 4
Federal Antitrust Laws................................................................................................................ 5
Federal Physician Payment Sunshine Act (Sunshine Act) ……………………………………. 6
Federal Bribery, Gratuity, and Conflict of Interest Statutes ....................................................... 6
The Foreign Corrupt Practices Act (FCPA)................................................................................ 7
Federal and State Exclusion, Debarment, or Suspension Provisions.......................................... 8
Privacy Requirements.................................................................................................................. 8
Regulatory Guidance and Industry Standards............................................................................. 9
Merck Ethics and Compliance Program................................................................................... 10
Office of Ethics and Divisional Compliance Departments....................................................... 10
Personal and Management Accountability............................................................................ 11
Reporting Concerns and Allegations of Misconduct ................................................................ 11
Reporting and Confidentiality............................................................................................... 11
Non-Retaliation..................................................................................................................... 12
Consequences of Unethical or Illegal Behavior…………………………………………….... 12
Merck Written Policies and Guidance....................................................................................... 13
Merck Written Guidance Establishing Ethical Behavior........................................................... 13
Code of Conduct.................................................................................................................... 13
Corporate Policies.................................................................................................................. 13
Headquarters Policies and Divisional Policies...................................................................... 14
Field Policy Letters ............................................................................................................... 14
Guiding Principles for Business Practices ............................................................................ 14
Training and Testing................................................................................................................. 15
Training Levels ..................................................................................................................... 15
Training Requirements.......................................................................................................... 16
Conclusion................................................................................................................................... 16
2 2
Merck Ethical Operating Standards Handbook
Public
PURPOSE
Merck is committed to complying with all laws and regulations that apply to its business. These
Ethical Operating Standards have been developed to help you comply with these laws and regulations.
In many cases, violations could lead to stiff penalties and other serious consequences for you and for
Merck. It is vital to adhere to these Ethical Operating Standards to maintain our good reputation and
to meet our obligations as a corporate citizen.
To avoid improper business conduct, you must consistently practice the values and standards that
have guided this Company for more than 130 years. They are the basis of our success and the way
we earn the trust of our customers every day.
U.S. LAWS AND REGULATIONS
FOOD AND DRUG ADMINISTRATION (FDA) REQUIREMENTS
The Federal Food, Drug, and Cosmetic Act (FDCA) is the comprehensive regulatory framework for
prescription drugs, covering research and development, manufacturing, and sales and marketing. It is
important for you to understand the following key principles under this law.
First, the FDCA prohibits the introduction of unapproved new drugs and the misbranding of approved
drugs. Off-label promotion, medical product information that is inconsistent with FDA-approved
labeling, is considered misbranding and can be a violation of the FDCA. Pharmaceutical companies
have incurred significant penalties as a result of off-label promotion.
Second, all promotional communications must be truthful and non-misleading, and must fairly
balance information about a product's benefits with information about a product's risks and limitations.
Third, the Prescription Drug Marketing Act (PDMA), which is part of the FDCA, prohibits any sale,
purchase, or tradeor any offer to do soof a prescription drug sample, voucher and/or coupon; and
the counterfeiting of or the offer to counterfeit vouchers and coupons. The PDMA is intended to
protect the market from counterfeit, adulterated, misbranded, or expired drugs, and one of the ways
it does so is by preventing samples from being introduced into the market for sale.
The consequences of FDCA violations can be significant, including fines and imprisonment.
GOVERNMENT PRICING REQUIREMENTS
U.S. federal and state governments pay Merck significant sums for the purchase and/or reimbursement
of Merck products. For that reason, they have a strong interest in enforcing pricing rules governing
reimbursement of pharmaceuticals and vaccines. It is essential that reports to the government
regarding product pricing are timely, accurate and disclose all required information. Merck is
committed to complying with all federal and state health care programs and government price
reporting requirements.
3 3
Merck Ethical Operating Standards Handbook
Public
Merck participates both directly and indirectly with various U.S. federal and state drug purchase
programs. Each of these programs has distinct rules that govern the prices that Merck may charge
government customers, and the rules are complex. Certain programs require payment of statutorily
defined rebates, such as Medicaid. Others establish a calculation for price limits, such as
procurements of pharmaceuticals by the Department of Veterans Affairs or the Department of
Defense for their beneficiaries, and the Section 340B Drug Pricing Program, which is managed by
the Department of Health and Human Services.
Merck Customer Contract Management group is responsible for collecting the relevant data and
performing the calculations required by each of the government programs. Merck employees must
recognize that all information provided to, or relied on, by Customer Contract Management must be
accurate and complete.
MEDICAID DRUG REBATE STATUTE AND MEDICARE LAWS
The Medicaid Drug Rebate Statute, administered by the Centers for Medicare and Medicaid Services
(CMS), requires manufacturers to enter into an agreement with the Secretary of the Department of
Health and Human Services (HHS) to provide rebates for their covered outpatient drugs, to help offset
government drug spending. Merck must accurately report prices and pay rebates as required by the
Medicaid Drug Rebate Statute to Medicaid.
Under the Medicaid Drug Rebate Statute, a manufacturer must give Medicaid the lowest price that it
offers to any purchaser, except some federal customers and some federally designated special
programs of care, which may receive a lower price. Manufacturers comply with this requirement
through Medicaid rebates. Merck enters into an agreement with the federal government to provide
quarterly rebates to state Medicaid programs, in exchange for Medicaid coverage of our products.
Civil penalties for Medicaid Drug Rebate Statute violations can be significant and levied daily for each
item of false information or the refusal of a verification survey request.
Medicare is also administered by CMS. Medicare is the federal health care insurance program for
older people, some disabled people and people with end-stage renal disease. Medicare Part A, also
known as the Hospital Insurance program, covers inpatient hospital services, skilled nursing facility,
home health, and hospice care. Medicare Part A is paid for through payroll deduction during an
individual’s working life. Medicare Part B, the Supplementary Medical Insurance program, helps pay
for physician, outpatient, home health, and preventive services. Part B is funded by general revenues
and beneficiary premiums. Medicare Part C, also known as the Medicare Advantage (MA) program,
allows beneficiaries to enroll in a private plan where the plan receives payments from Medicare to
provide Medicare-covered benefits, including hospital and physician services, and in most cases,
prescription drug benefits. Medicare Part D is the outpatient prescription drug benefit, delivered
through private plans that contract with Medicare, either stand-alone prescription drug plans or
Medicare Advantage prescription drug plans.
Depending on the violation, civil penalties can be imposed. Suspensions of enrollment of Medicare
beneficiaries, payment to the MA organization, and marketing activities to Medicare beneficiaries are
also possible. The enrollment, payment, and marketing sanctions continue in effect until CMS is
satisfied that the violation has been corrected and is not likely to recur.
4 4
Merck Ethical Operating Standards Handbook
Public
FEDERAL AND STATE ANTI-KICKBACK LAWS
The federal Anti-Kickback Statute impacts many of Merck activities in the United States every day.
This law prohibits offering, paying, soliciting, or receiving any remuneration to induce the purchase,
order or recommendation of any drug that may be paid for by a federal health care program.
Remuneration is defined broadly to include payment or any transfer of value made directly or
indirectly, overtly or covertly, in cash or in kind. This law is enforced to prevent fraud, over-
utilization, and excessive costs in Medicare, Medicaid, and other federal health care programs.
Activities that seek to improperly influence the decision making of a health care professional may
violate this law. For example, paying physicians for services that are unnecessary, paying for services
at above-market value, offering an educational grant to a physician to switch to a company’s drugs,
providing services aimed at improving a customer’s business operations or offsetting a customer’s
expenses are types of arrangements that may violate this law. Certain arrangements with other
stakeholders, such as payments to hospitals, pharmacies, managed care organizations, preferred
provider organizations or integrated delivery networks, can also violate the anti-kickback law. As a
result, you must consider this statute carefully when entering into these types of relationships.
A violation of the Anti-Kickback Statute can carry severe penalties, including civil monetary penalties
and criminal penalties. Additionally, violation of the Anti-Kickback Statute may lead to exclusion
from Medicare, Medicaid, and other federal health care programs.
In parallel with the federal Anti-Kickback Statute, many states have adopted their own anti-
kickback laws.
FEDERAL AND STATE FALSE CLAIMS ACTS
The Federal False Claims Act (FCA) imposes substantial civil penalties on any corporation or
individual who knowingly makes or causes another to make a false claim or a false representation in
a claim for approval or payment to the United States government.
A false claim is “knowinglymade if the corporation or individual acts with knowledge of the
falsity of the claim or representation, or with reckless disregard or willful blindness to the truth or
falsity of the claim or representation made to the government.
The FCA also covers “reverse false claims,” in which a corporation or an individual knowingly makes
a false representation regarding an obligation it owes to the United States, such as falsifying records
reflecting an amount owed to the United States. In addition, a “reverse false claim” is also made if a
corporation or an individual knowingly makes a false representation to a contractor or subcontractor
of the United States.
The U.S. federal and state governments have entered into a number of settlement agreements with
pharmaceutical manufacturers regarding allegations that the manufacturers violated the FCA by causing
federal and state health care programs to be overcharged. Affected programs include Medicaid,
Medicare, TRICARE, the Veterans Administration Federal Supply Schedule, Section 340B drug pricing
programs, the Federal Employee Health Benefit Plans, and Indian health clinics, among others.
5 5
Merck Ethical Operating Standards Handbook
Public
The underlying misconduct of these settlements included paying kickbacks to physicians, causing
health care providers to seek reimbursement from the government for non-reimbursable, off-label
indications, and submitting false claims to the government regarding pricing information, such as
Average Manufacturer Price and Best Price under the Medicaid rules. Often, the violation of the
other statutes previously discussed, such as the anti-kickback statutes, FDCA, or PDMA, can also
cause a company to submit a false claim or to cause another to submit a false claim.
Lastly, the FCA is violated by the submission of a false claim for payment, regardless of whether
the claim is paid. For that reason, we must exercise caution in advising health care providers about
government reimbursement for Merck pharmaceuticals and vaccines.
A number of states have adopted state false claims act statutes that are largely modeled after the
federal statute.
Civil and criminal penalties for FCA violations can be significant. Moreover, violations of the FCA
could lead to our exclusion from Medicaid, Medicare, and other government reimbursement programs.
FEDERAL ANTITRUST LAWS
Antitrust laws are concerned with promoting healthy competition within industries and ensuring that
no single entity gains undue market power to the detriment of consumers. Not only do antitrust
lawsuits and investigations significantly disrupt business operations, but the penalties for violating the
antitrust laws can be significant, including monetary damages and imprisonment for the most serious
violations. One key trigger of antitrust scrutiny is agreements between competitors. Any agreement
with competitors about commercially sensitive topics (such as the pricing of products or services,
markets or customers to whom competitors may sell, or employees’ wages and benefits), is likely to
be considered an automatic antitrust violation and must be avoided. Even where there is no explicit
agreement between competitors, certain types of activities—such as frequent meetings or
communications with competitors, or coordinated market behavior, can support an inference that an
agreement has been reached. As a result, Merck employees should avoid all communications with
competitors on commercially sensitive topics (like pricing or R&D or marketing strategies), and
should be mindful of the need to avoid even creating the impression that improper collusion may have
occurred. Another important trigger of antitrust scrutiny is the potential exclusion of competitors in
areas where Merck may have market power. Merck employees should therefore enlist the assistance
of Merck counsel when considering strategies in areas where Merck may have a high share, or for any
strategy that could have the effect of excluding a competitor.
Price discrimination can also violate antitrust laws. Price discrimination is the act of offering different
prices to competing resellers for similar goods. Not every pricing differential is an antitrust
violationin fact, there are many circumstances where price discrimination is allowed because it
promotes market competition. Since the rules are complex, instances where price discrimination is
being contemplated should be reviewed in advance by Merck counsel.
Compliance with Merck policies, as well as consultation with the Office of General Counsel, is critical
to steer clear of potential antitrust violations.
Merck Ethical Operating Standards Handbook
6
Public
FEDERAL PHYSICIAN PAYMENT SUNSHINE ACT (SUNSHINE ACT)
The Sunshine Act requires manufacturers of drugs, medical devices, and biologicals that are
reimbursed or “covered” by U.S. Federal health care programs to track and report certain payments
and transfers of value made to designated healthcare providers and teaching hospitals (collectively,
“Covered Recipients”). Almost any payment or transfer of value made by applicable manufacturers
to Covered Recipients is reportable. Examples include, but are not limited to:
Journal reprints (both digital and hardcopy), reference textbooks, and other publications
Speaker and consulting fees
Lodging and travel expenses incurred while performing contracted services
Royalties and licensing fees
Meals
Research-related expenses
Certain grant payments
Under the law, Merck must track and annually report such payments and transfers of value to the
Centers for Medicare and Medicaid Services (CMS). CMS publishes these data annually.
Failure to timely submit complete and accurate information can result in monetary penalties.
FEDERAL BRIBERY, GRATUITY, AND CONFLICT OF INTEREST STATUTES
The federal bribery statute prohibits offering a bribe or gratuity to a public official. Specifically, it is
illegal to directly or indirectly give, offer, or promise anything of value to a public official to influence
any official act, any act of fraud on the United States, or any action or omission that violates the lawful
duty of that person.
Public officials can include any Member of Congress; any officer, employee, or person acting for or
on behalf of the United States or any departments, agencies, or branches of the federal government;
any former public official; or any person selected to be a public official. The penalty is a fine of up
to three times the amount of the bribe and/or imprisonment.
The federal conflict of interest statute prohibits giving, promising, or offering any compensation for
representational services to any employee of any branch or agency of the federal government. This
includes Members of Congress, Commissioners, Members and Commissioners Elect, and Federal
Judges.
The statute relates to any matter in which the United States is a party or has a direct or substantial
interest before any government office or agency. It does not include matters that are part of the
government employee’s proper discharge of lawful duties.
The penalty for violating this statute is imprisonment and/or either a significant fine for each violation
or a penalty in the amount of the compensation offered, whichever is greater.
Many states have also adopted similar laws that apply to state government officials.
7 7
Merck Ethical Operating Standards Handbook
Public
THE FOREIGN CORRUPT PRACTICES ACT (FCPA)
The U.S. Foreign Corrupt Practices Act (FCPA), which is essentially an anti-bribery statute, applies
to U.S.-based companies as well as subsidiaries and agents under their control, whether or not they
are in the United States. The FCPA prohibits giving, offering, promising, or paying money or
anything of value, directly or indirectly, including by an intermediary or third party agent, to a foreign
official for the purpose of obtaining or retaining business or obtaining an improper advantage. The
FCPA also requires companies to maintain accurate books and records and to maintain a system of
internal controls. There is no materiality requirement under the FCPA, and a bribe of any amount
may be subject to prosecution.
The FCPA applies to our overseas operations, to its foreign subsidiaries, and to any third parties acting
for or on behalf of Merck and its subsidiaries.
The term “foreign officials” under the FCPA includes, but is not limited to, the following:
Direct employees of foreign governments performing government functions, such as product
approvals, pricing, reimbursement, and government purchasing.
Those engaged by foreign governments to provide advice involving a government function,
such as experts, consultants, and members of advisory panels.
Those employed by foreign government agencies, which includes government-owned or
government-controlled businesses that perform a function that in other countries is performed
privately, such as physicians and purchasing agents at state-owned hospitals.
Officers of political parties, candidates for political office, and members of public international
organizations, such as the United Nations, World Bank, and World Health Organization, as
well as their staffs, business partners, close associates, and family members.
Merck requires that any payments made or benefits provided, directly or indirectly, to foreign officials
be subject to evaluation and fact-finding in accordance with approved standards. Those standards
require full and accurate documentation of the appropriateness of providing the payment, and pre-
approval of the payment from the appropriate organizations and at the appropriate level of
management. Merck also requires the completion of risk-based anti-corruption due diligence on third
parties who conduct business on our behalf or who Merck authorizes to engage in certain business
activities.
A more complete description of the FCPA and related standards for interacting with foreign officials
are set forth in Corporate Policy 5–Prevention of Bribery and Corruption (Ethical Business Practices)
and related resources. Any question regarding compliance with the FCPA or related standards may
be referred to your manager, the Office of General Counsel, your Divisional Compliance Department,
or the Office of Ethics.
Individuals and Corporations who violate the anti-bribery provisions of the FCPA are subject to
significant civil fines as well as criminal penalties and imprisonment for individuals involved.
Penalties may also include fines based upon repayment of the benefit obtained or sought. Moreover,
violations of the accounting provisions of the FCPA are subject to separate penalties.
8 8
Merck Ethical Operating Standards Handbook
Public
FEDERAL AND STATE EXCLUSION, DEBARMENT, OR SUSPENSION PROVISIONS
To protect the public interest, the federal government can exclude, debar, or suspend individuals or
corporations from conducting business with the federal government and/or with parties that conduct
business with the federal government. Any alleged or actual violation of the laws discussed in this
summary could be grounds for this exclusion, debarment, or suspension.
The implications of exclusion, debarment, or suspension are extensive. If a company is excluded,
debarred, or suspended from doing business with the federal government, it cannot participate in
Medicare, Medicaid, or other federal health care programs. The company is also precluded from
providing any of its products to any other federal government agencies.
Just as the federal government may exclude certain individuals and corporations, states have also
established rules covering exclusion, debarment, or suspension.
Merck policy requires employees to notify a manager if the employee becomes excluded, debarred,
suspended, or convicted of a health care-related crime. Further, Merck employees are required to
report if any other employee or any individual or entity acting on behalf of Merck becomes excluded,
debarred, suspended, or convicted of a health care-related crime. Any current or prospective
employee or person or entity who acts on behalf of Merck who falls within this definition is
considered to be an “ineligible person.”
Merck is required to screen all individuals and entities who may work at Merck or act on behalf of
Merck pursuant to Divisional procedures to ensure that they are not ineligible persons. Screening will
occur before employment begins and on an annual basis. Merck policy precludes the Company from
billing a federal health care program for items or services from an ineligible person, and it may not
use federal funds to pay for items or services from an ineligible person. Merck will consider removal
of an ineligible employee, contractor, subcontractor or agent. Such consideration will be based on the
individual’s role and responsibility.
Additionally, certain employees are required to certify in the Annual Ethics & Policy Certification that
they are not ineligible persons. As required per our Procurement and Supplier Relations, Corporate
Policy 6, business areas responsible for contracts and contractors are responsible to ensure the
ineligible persons screening is complete. For additional information regarding obligations relative to
exclusion, debarment and suspension, refer to the Global Human Resources policy, Corporate Policy
17.
PRIVACY REQUIREMENTS
Privacy in the context of U.S. law is a broad concept that generally relates to the extent of people’s
rights to make decisions about themselves, including about how personal information about them may
be collected, observed, used, or shared with others. Privacy requirements can be triggered in the context
of programs and activities that involve information about people and/or interactions with people.
Privacy requirements are developed from laws, regulations, legal/regulatory decisions, and Merck
corporate policies related to protecting information about people and controlling the manner in which
that information is used and disclosed.Types of privacy laws and regulations that are relevant to
business activities at Merck include state and federal laws and statutes, health information privacy laws,
9 9
Merck Ethical Operating Standards Handbook
Public
communications privacy laws, data security laws, and unfair/deceptive trade practice and consumer
protection laws.
Health information privacy laws relate to the use and disclosure of individually identifiable personal
health information (PHI). These include the Federal Health Insurance Portability and Accountability
Act (HIPAA), the Federal Health Information Technology for Economic and Clinical Health Act
(HITECH), and various State health information privacy laws. State privacy laws, such as the
California Privacy Rights Act (CPRA) impose specific requirements for transparency, notices,
consent processes, limits on collection and sharing of information, and access, deletion, suppression
and correction of data. Certain states also provide rights such as “do not sell” and limits for tracking
user behavior. Communication privacy laws impose requirements on the method or channel of
communication (e.g., e-mail, social media, apps, telephone (including SMS), fax, and other online
regulations), how and when the channel is used, appropriate recipients, and the content of the
communication. Data security laws set requirements to protect the security and confidentiality of
certain types of personal information as well as requirements for notification to affected individuals
in the event of an unauthorized access to certain types of personal information. And more recently,
states have been enacting privacy laws and expectations, which depending on the vehicle of delivery
or collection, may extend beyond the jurisdiction of that state.
Unfair/deceptive trade practice and consumer protection laws establish minimum requirements for all
communications with consumers and customers and may also set minimum standards for the manner
in which personal information is secured, subject to more restrictive requirements established by
health information privacy laws, state privacy laws, communications privacy laws, and data security
laws. Additionally, in light of the rapid, ongoing evolution of mobile and connected data platforms
as well as the use of data analytics across business sectors, some states are considering broader
consumer privacy laws providing further protections related to the collection, tracking, and sale of
personal information. In fact, multiple states have already enacted new and broader privacy laws
effective on or after January 1, 2023.
Merck Privacy Program, policies and implementing standards have been developed to facilitate
compliance with all applicable privacy laws and regulations. For a more complete description, refer
to Corporate Policy 13 – Information Management and Protection, Corporate Policy 13.2 – Global
Privacy and Data Protection, and Corporate Policy 13.10 – Global Workplace Privacy. For
additional information, visit the Privacy Hub - Home (merck.com)
REGULATORY GUIDANCE AND INDUSTRY STANDARDS
In addition to the laws discussed above, there are two important sets of standards that shape how
Merck employees should act. Both of these standards have been incorporated into Merck policies.
In 2003, the Office of the Inspector General (OIG) of the Department of Health and Human Services
(HHS) issued guidance for pharmaceutical manufacturers’ compliance programs. HHS OIG is
responsible for providing objective oversight to promote the economy, efficiency, effectiveness, and
integrity of HHS programs by conducting, among other activities, a nationwide network of audits,
investigations, and inspections. The 2003 guidance signaled three areas that OIG is particularly
concerned about: the integrity of pricing data provided to the federal government to establish payment
amounts; kickbacks and other illegal remuneration to health care professionals; and prescription drug
samples, vouchers and/or coupons.
10 10
Merck Ethical Operating Standards Handbook
Public
In 2022, the Pharmaceutical Research and Manufacturers of America (PhRMA) updated its voluntary
ethical code on Interactions with Healthcare Professionals. This code addresses pharmaceutical
manufacturers’ relationships with health care professionals, and establishes guidance concerning
several practices, including: informational presentations by pharmaceutical company representatives
and accompanying meals; sponsorship or financial support for third party educational or professional
meetings; consulting relationships with physicians; speaker programs and speaker training meetings;
scholarships and educational funds; and the prohibited use of non-educational and practice-related
items (e.g., “reminder-items” with company or product logos).
Merck policies and practices have been developed to be consistent with the OIG guidance and the
PhRMA Code, as well as to comply fully with all relevant laws and regulations. By following our
policies and Ethical Operating Standards, you can promote the integrity of Merck Field-based and
Marketing-related operations and avoid behavior that can be costly to you and to Merck.
MERCK ETHICS AND COMPLIANCE PROGRAM
OFFICE OF ETHICS AND DIVISIONAL COMPLIANCE DEPARTMENTS
The Ethics and Compliance Office (ECO) is responsible for maintaining a companywide compliance
program. ECO is led by the Chief Ethics and Compliance Officer, who is responsible for Merck’s
corporate-wide Office of Ethics, and the Divisional Compliance Officers who lead the Divisional
Compliance Departments.
The Office of Ethics is responsible for managing the Company’s Code of Conduct and the speak up
program, providing ethics guidance, developing training and communications, and investigating
allegations of policy violations in the U.S.
HH Ethics and Compliance is responsible for partnering with Human Health to ensure compliance
with the U.S. laws and regulations governing Medicare, Medicaid, and other federal, state, and local
health care programs, as well as the design, development, and implementation of business practices
and policies guiding U.S. marketing and sales activities and HH Headquarters directed activities. In
collaboration with HH, HH Ethics and Compliance developed a Compliance Plan (the Plan) modeled
after the OIG’s seven elements of an effective compliance program. The Plan is designed to ensure
compliance with Federal healthcare program requirements, federal and state transparency
requirements, and FDA requirements regarding the selling, marketing, promotion and dissemination
of information about Merck products. To learn more about the HH Compliance Program and the HH
Compliance Plan, please visit the HH Ethics and Compliance intranet site at
ghhcompliance.merck.com.
If you have questions about the laws and regulations that apply to Merck business or the spirit and
letter of Merck policies or concerns about illegal or unethical behavior, you should raise them with
your manager or the representatives of the Ethics and Compliance Office (ECO).
11 11
Merck Ethical Operating Standards Handbook
Public
Personal and Management Accountability
Corporate conduct cannot be separated from individual behavior. There are potential consequences for
each action we take, so it is every employee’s responsibility to ensure that our actions reflect positively
on our Company and uphold Merck traditions. By adhering to our ethical business practices, we
demonstrate an understanding of and a respect for the laws that regulate our business and the ethical
principles that serve as the foundation of those laws.
Every Merck employee must comply with the letter and spirit of Merck policies and the federal and
state laws and regulations that apply to Merck business. Compliance and ethics are critical to the
success of Merck. Everyone is responsible for compliance and ethics. You are also expected to
demonstrate executional excellence when conducting every activity. You will be held personally
accountable if you fail to comply with Merck policies and relevant laws and regulations or if you fail
to report known inappropriate or unethical behavior of other employees and those involved in Merck
business.
This includes your responsibility as a manager and/or an employee to protect Merck assets and operate
within the
Grants of Authority.
REPORTING CONCERNS AND ALLEGATIONS OF MISCONDUCT
If you see something, say something. Not only is it the right thing to do, but safeguarding our reputation
is critical to our mission of continuing to bring lifesaving products to our patients.
You can voice any concerns of misconduct to a manager, human resources, global security, legal,
compliance or the Office of Ethics, so that the matter can be investigated and remediated as appropriate.
Also, the Speak Up tool at msdethics.com that is operated by an independent third party service,
available 24 hours a day, 7 days a week and allows for reporting in 28 different languages. The
information provided through msdethics.com will be relayed to the Office of Ethics and the appropriate
company representative will follow-up with the employee. When employees enter a report using
msdethics.com, they may remain anonymous, where permitted by law.
Reporting and Confidentiality
Merck takes all reported concerns seriously, and when appropriate, will investigate to determine if
there has been a violation. These concerns can include conduct inconsistent with the Company’s
policies, practices, values, and standards. If you report an alleged violation, Merck will make every
reasonable effort to keep your identity confidential while conducting a thorough and fair investigation
as required under the law. If you wish, you may remain anonymous when making a report.
In situations where an investigation is appropriate, it is imperative that you refrain from discussing
with colleagues or co-workers your contact with the Office of Ethics, Divisional Compliance
Department, Office of General Counsel, or Human Resources Department. This discretion will help
the Company maintain confidentiality of the investigation and your identity.
To learn more about raising concerns, please visit the Code of Conduct Speak Up page and
Corporate Policy 15 Reporting and Responding to Misconduct.
12 12
Merck Ethical Operating Standards Handbook
Public
Non-Retaliation
Merck will not tolerate retaliation against any employee for raising a business practices issue in good
faith. “Good faith” means that you have made a genuine attempt to provide honest and accurate
information even if you are later proven to be mistaken.
The fact that an employee has raised concerns in good faith, or has provided information in an
investigation, cannot be a basis for denial of benefits, termination, demotion, suspension, threats,
harassment, or discrimination. Similarly, if you are aware that a colleague has raised concerns, you
are expected to treat that person in a courteous and respectful manner. Certainly, do not engage in
behavior that might alienate or intimidate colleagues.
This protection extends to anyone giving information in relation to an investigation. If you or others
have experienced an act of retaliation, report this behavior to your manager, the Office of Ethics, or
your Divisional Compliance Department.
For more information, please visit the Code of Conduct Speak Up page and Corporate Policy 15
Reporting and Responding to Misconduct
CONSEQUENCES OF UNETHICAL OR ILLEGAL BEHAVIOR
Violations of the laws and regulations discussed in this handbook and Merck policies can not only
have a negative impact on our reputation; they can result in criminal and/or civil penalties to both the
Company and the individual employee. Urging employees to report suspected misconduct is a
necessary part of Merck compliance activities. Stopping misconduct before it occurs and addressing
misconduct as soon as possible gives Merck the opportunity to limit damage to the business
community and to its reputation. Early reporting also helps Merck work with law enforcement
authorities to ensure that the responsible parties are held accountable.
In addition to criminal and civil penalties, failure to comply with Merck standards and to report
suspected misconduct can have serious consequences. For Merck employees, compliance violations
can result in disciplinary action up to and including termination from employment at Merck. For
contractors, such violations may cause Merck to terminate the contractual relationship.
Remember to refer to the Merck Code of Conduct Values-Based Decision questions when assessing
whether conduct can lead to violation of laws, regulations, or Merck policies. The Code of Conduct
Values-Based Decision questions ask every employee to consider:
Could my conduct or decision harm anyone or anything?
Will my conduct violate the trust of customers, patients, shareholders or other stakeholders?
Am I willing to be held accountable for this decision or action if it appears in the media?
Do I know for certain that my proposed action is consistent with the letter and spirit of our
Company policies, as well as applicable laws and regulations?
Once you answer these questions, if you are still unsure about what to do, contact your manager, the
Office of Ethics, the Divisional Compliance Officer, or the Office of General Counsel.
13 13
Merck Ethical Operating Standards Handbook
Public
MERCK WRITTEN POLICIES AND GUIDANCE
Regardless of how general or detailed the discussion of the laws and regulations that apply to Merck
business may be, this handbook cannot possibly anticipate all the challenges you may face on the job.
That is why there are additional resources we can use when we have questions about business conduct.
MERCK WRITTEN GUIDANCE ESTABLISHING ETHICAL BEHAVIOR
Merck has developed resource materials that set forth the Company’s expectations for ethical
behavior. It is important that you familiarize yourself with the materials that apply to all employees
at Merck as well as those that apply to your specific department. Bear in mind, these are evolving
materials and will change or grow over time. The specific materials described below will be reviewed
on a regular basis and updated as appropriate.
Code of Conduct
Merck code of conduct, Our Values and Standards, is our universal statement of the values, standards,
and ethical principles that guide our daily operations. The code of conduct applies to everyone
conducting business on behalf of Merck, and stresses the need to be truthful in our relationships with
our business partners, the public and applicable government agencies. All new employees are
required to review the code of conduct. You can review the code of conduct:
Online: codeofconduct.merck.com
From your device: Visit the Merck App Store:
https://appstore.merck.com/search/Code%20of%20conduct
Corporate Policies
Corporate policies apply to all employees and establish Merck standards of conduct. Be sure to
familiarize yourself with the corporate policies relevant to your responsibilities. These policies can
be found on the Code of Conduct website at policy.merck.com.
Policies include, but are not limited to:
Customer Facing, Marketing and Business Practices (Corporate Policy 4)
Prevention of Bribery and Corruption (Corporate Policy 5)
Interacting with ex-U.S. HCPs and Other Government Officials (5.2.1)
Third Party Due Diligence Standard (5.2.2)
Procurement and Supplier Relations (Corporate Policy 6)
Information Management and Protection (Corporate Policy 13)
Global Privacy and Data Protection (Policy 13.2)
Merck and MSD Policy on Social Media
Reporting and Responding to Misconduct (Corporate Policy 15)
Global Human Resources (Corporate Policy 17)
Effect of Exclusions, Debarments, Suspensions and Healthcare-Related Criminal
Convictions; Reporting and Screening
14 14
Merck Ethical Operating Standards Handbook
Public
Information and resources pertaining to Grants of Authority can be found on the Merck intranet.
Headquarters Policies and Divisional Policies
Headquarters Policies and Divisional Policies have been written to provide employees with the
direction they need to perform activities that comply with both the letter and the spirit of applicable
laws and regulations. It is your responsibility to familiarize yourself with, and adhere to, any applicable
guidance or policy while performing covered activities. You can review Headquarters Policies for HH
employees at https://collaboration.merck.com/sites/ghh_ethics_complianc/SitePages/HQ.aspx
Field Policy Letters
U.S. Field Policy Letters describe applicable legal and regulatory requirements for employees. These
letters reflect the commitment of the Human Health Field-based organizations to a high level of ethical
conduct when working with health care professionals and customers.
Merck Field-based employees are required to know and act in accordance with the content of the Field
Policy Letters. Contact your manager if you have any questions about the policy letters, or review the
letters on the Merck intranet at
https://collaboration.merck.com/sites/ghh_ethics_complianc/SitePages/Field_Policy_Letters.aspx
Keep in mind that all discussions between Field-based employees and healthcare providers may be
considered promotion and are closely regulated.
Guiding Principles for Business Practices
Merck Guiding Principles for Business Practices build a bridge that connects applicable laws,
regulations, Merck Corporate and Divisional Policies, and other guidance provided by Merck. The
Guiding Principles exist to ensure that all activities have a well-articulated business purpose, are
implemented to the highest standards of ethics and integrity, are consistent with Company policies and
applicable industry laws and regulations, and have the utmost regard for patient health and safety.
The Guiding Principles are as follows:
Principle 1. Focus interactions with the medical and scientific community on business and scientific
objectives that support the Company’s mission of Putting Patients First.
Principle 2. For Company-sponsored or supported activities, comply with all applicable laws,
regulations, and industry or professional Codes of Conduct of both the host country and the resident
country of individual participants or organizations.
Principle 3. Compensate for services at fair market value, purchasing only those services that are
required to address the business issue/need at hand.
Principle 4. Ensure that offering something of value to members of the medical and scientific
community does not have the appearance or the intent of influencing regulatory, formulary, pricing,
or reimbursement decisions or inducing or rewarding the referral, recommendation, utilization, or
prescribing of Merck products.
15 15
Merck Ethical Operating Standards Handbook
Public
Principle 5. Maintain a business-like atmosphere for all interactions with the medical and scientific
community, avoiding lavishness or extravagance, as well as the appearance of such.
Principle 6. Ensure that decision making regarding activities associated with grants, payments for
services to the medical and scientific community, and the generation and reporting of clinical
information is free of any inappropriate commercial or other influences (that is, influences that are not
aligned with the stated objective of the activity).
Principle 7. Apply good business judgment to all communications and documentation involving our
interaction with the medical and scientific community, and ensure proper implementation of activities
(e.g., training, documentation, tracking, reporting, and follow-up).
Principle 8. Conduct activities and interactions with the medical and scientific community in a manner
that protects our intellectual property and respects that of others.
Principle 9. Ensure that all communications shared with the medical and scientific community are
based on accurate and balanced scientific information.
Principle 10. Ensure that selection of members from the medical and scientific community is based
on their areas of expertise, experience, and other appropriate, objective criteria aligned with the stated
purposes of the activity.
TRAINING AND TESTING
The laws and regulations governing Merck business and Merck policies are too important to rely on
informal communications. Merck recognizes training is critical, and Merck employees in the United
States who are involved in the sales and marketing of pharmaceutical products, as well as Merck
employees with certain cross-functional responsibilities, will receive training and testing in the laws
and regulations discussed in this handbook and other relevant Merck policy documents, including the
Code of Conduct and certain Merck corporate policies.
Thorough, engaging training programs will ensure employees are equipped with the knowledge to
define, explain, and apply the rules regarding the regulated environment in which Merck operates.
Training Levels
Merck employees, as well as certain contractors, subcontractors, and agents of Merck must complete
annual web-based Ethical Operating Standards (EOS) Training, the most fundamental level of training.
Employees who take this training will be expected to review the training materials, acknowledge their
understanding of the materials, and complete a certification test.
Ethical Operating Standards (EOS) Training provides key information regarding Merck Ethical
Operating Standards. This includes the laws and regulations governing our industry, Merck Ethics
and Compliance Program, and the Guiding Principles governing our activities.
Compliance Fundamentals Training provides a broad overview of how the Guiding Principles apply
to specific activities. The training describes these activities, associated risks, and high-level roles and
16 16
Merck Ethical Operating Standards Handbook
Public
expectations. Employees who engage in certain activities involving U.S. health care professionals
(HCPs), customers, or institutions are required to take Compliance Fundamentals Training. It is not
intended to provide details about the execution of particular activities. Those details are provided in
the Mastery Training level.
Mastery Training is the most comprehensive level of training. Mastery Training is focused on
implementation excellence and provides in-depth training on the processes, procedures, check-lists,
and other requirements for executing specific activities. All employees who execute and direct
activities must complete Mastery Training on the activity before they can direct or execute that activity.
First-line managers of employees who direct or execute an activity must complete Mastery Training
on the activity before they can provide oversight on the activity. The activity leader listed at the top
of each Headquarters Policy will instruct you regarding your Mastery Training requirements for the
activity.
Training Requirements
All current employees described above must participate in annual EOS, Compliance Fundamentals,
and Mastery Training, as appropriate. If you receive new responsibilities following the annual
training cycle, you must complete all relevant training prior to assuming the new responsibilities.
Managers must ensure their employees complete all training prior to beginning any new
responsibilities. You and your manager are responsible for closely overseeing your training to ensure
it is consistent with your new responsibilities.
CONCLUSION
To ensure that we know our ethical and legal obligations, Merck prepared this handbook setting our
Ethical Operating Standards for Merck employees. These written standards focus on the need for each
of us to comply with U.S. federal and state laws and regulations so that Merck will continue to be in
good standing with all, including our government business partners. By consistently practicing the
values and standards that have guided this Company for more than 130 years, we will continue to earn
the trust of our customers every day.
Public
Public
This document was revised and distributed
in December 2023 by Merck & Co., Inc.